The National MDS Natural History Study

design of an integrated data and sample biorepository to promote research studies in myelodysplastic syndromes

Mikkael A. Sekeres, Steven D. Gore, Donald M. Stablein, Nancy DiFronzo, Gregory A. Abel, Amy E. DeZern, Jesse D. Troy, Dana E. Rollison, John W. Thomas, Myron A. Waclawiw, Jane Jijun Liu, Tareq Al Baghdadi, Matthew J. Walter, Rafael Bejar, Edward J. Gorak, Daniel T. Starczynowski, James M Foran, James R Cerhan, Lynn C. Moscinski, Rami S. Komrokji & 2 others H. Joachim Deeg, Pearlie K. Epling-Burnette

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Myelodysplastic syndromes (MDS), a spectrum of heterogeneous hematopoietic stem cell diseases, vary in clinical severity, response to therapy, and propensity toward progression to acute myeloid leukemia. These are acquired clonal disorders resulting from somatic mutations within the hematopoietic stem or progenitor cell population. Understanding the natural history and the risk of developing leukemia and other adverse outcomes is dependent on access to well-annotated biospecimens linked to robust clinical and molecular data. To facilitate the acquisition and distribution of MDS biospecimens to the wider scientific community and support scientific discovery in this disease, the National MDS Natural History study was initiated by the National Heart, Lung, and Blood Institute (NHLBI) and is being conducted in collaboration with community hospitals and academic medical centers supported by the National Cancer Institute (NCI). The study will recruit up to 2000 MDS patients or overlapping myeloproliferative neoplasms (MDS/MPN) and up to 500 cases of idiopathic cytopenia of undetermined significance (ICUS). The National MDS Natural History Study (NCT02775383) will offer the world’s largest disease-focused tissue biobank linked to longitudinal clinical and molecular data in MDS. Here, we report on the study design features and describe the vanguard phase of 200 cases. The study assembles a comprehensive clinical database, quality of life results, laboratory data, histopathology slides and images, genetic information, hematopoietic and germline tissues representing high-quality biospecimens and data from diverse centers across the United States. These resources will be available to the scientific community for investigator-initiated research.

Original languageEnglish (US)
JournalLeukemia and Lymphoma
DOIs
StatePublished - Jan 1 2019

Fingerprint

Myelodysplastic Syndromes
Natural History
Research
Hematopoietic Stem Cells
National Heart, Lung, and Blood Institute (U.S.)
National Cancer Institute (U.S.)
Community Hospital
Acute Myeloid Leukemia
Leukemia
Quality of Life
Research Personnel
Databases
Mutation
Population
Neoplasms

Keywords

  • biorepository
  • Myelodysplastic syndromes
  • natural history
  • quality of life

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

The National MDS Natural History Study : design of an integrated data and sample biorepository to promote research studies in myelodysplastic syndromes. / Sekeres, Mikkael A.; Gore, Steven D.; Stablein, Donald M.; DiFronzo, Nancy; Abel, Gregory A.; DeZern, Amy E.; Troy, Jesse D.; Rollison, Dana E.; Thomas, John W.; Waclawiw, Myron A.; Liu, Jane Jijun; Al Baghdadi, Tareq; Walter, Matthew J.; Bejar, Rafael; Gorak, Edward J.; Starczynowski, Daniel T.; Foran, James M; Cerhan, James R; Moscinski, Lynn C.; Komrokji, Rami S.; Deeg, H. Joachim; Epling-Burnette, Pearlie K.

In: Leukemia and Lymphoma, 01.01.2019.

Research output: Contribution to journalArticle

Sekeres, MA, Gore, SD, Stablein, DM, DiFronzo, N, Abel, GA, DeZern, AE, Troy, JD, Rollison, DE, Thomas, JW, Waclawiw, MA, Liu, JJ, Al Baghdadi, T, Walter, MJ, Bejar, R, Gorak, EJ, Starczynowski, DT, Foran, JM, Cerhan, JR, Moscinski, LC, Komrokji, RS, Deeg, HJ & Epling-Burnette, PK 2019, 'The National MDS Natural History Study: design of an integrated data and sample biorepository to promote research studies in myelodysplastic syndromes', Leukemia and Lymphoma. https://doi.org/10.1080/10428194.2019.1616186
Sekeres, Mikkael A. ; Gore, Steven D. ; Stablein, Donald M. ; DiFronzo, Nancy ; Abel, Gregory A. ; DeZern, Amy E. ; Troy, Jesse D. ; Rollison, Dana E. ; Thomas, John W. ; Waclawiw, Myron A. ; Liu, Jane Jijun ; Al Baghdadi, Tareq ; Walter, Matthew J. ; Bejar, Rafael ; Gorak, Edward J. ; Starczynowski, Daniel T. ; Foran, James M ; Cerhan, James R ; Moscinski, Lynn C. ; Komrokji, Rami S. ; Deeg, H. Joachim ; Epling-Burnette, Pearlie K. / The National MDS Natural History Study : design of an integrated data and sample biorepository to promote research studies in myelodysplastic syndromes. In: Leukemia and Lymphoma. 2019.
@article{2841ca882db548aba5b86074898f16ac,
title = "The National MDS Natural History Study: design of an integrated data and sample biorepository to promote research studies in myelodysplastic syndromes",
abstract = "Myelodysplastic syndromes (MDS), a spectrum of heterogeneous hematopoietic stem cell diseases, vary in clinical severity, response to therapy, and propensity toward progression to acute myeloid leukemia. These are acquired clonal disorders resulting from somatic mutations within the hematopoietic stem or progenitor cell population. Understanding the natural history and the risk of developing leukemia and other adverse outcomes is dependent on access to well-annotated biospecimens linked to robust clinical and molecular data. To facilitate the acquisition and distribution of MDS biospecimens to the wider scientific community and support scientific discovery in this disease, the National MDS Natural History study was initiated by the National Heart, Lung, and Blood Institute (NHLBI) and is being conducted in collaboration with community hospitals and academic medical centers supported by the National Cancer Institute (NCI). The study will recruit up to 2000 MDS patients or overlapping myeloproliferative neoplasms (MDS/MPN) and up to 500 cases of idiopathic cytopenia of undetermined significance (ICUS). The National MDS Natural History Study (NCT02775383) will offer the world’s largest disease-focused tissue biobank linked to longitudinal clinical and molecular data in MDS. Here, we report on the study design features and describe the vanguard phase of 200 cases. The study assembles a comprehensive clinical database, quality of life results, laboratory data, histopathology slides and images, genetic information, hematopoietic and germline tissues representing high-quality biospecimens and data from diverse centers across the United States. These resources will be available to the scientific community for investigator-initiated research.",
keywords = "biorepository, Myelodysplastic syndromes, natural history, quality of life",
author = "Sekeres, {Mikkael A.} and Gore, {Steven D.} and Stablein, {Donald M.} and Nancy DiFronzo and Abel, {Gregory A.} and DeZern, {Amy E.} and Troy, {Jesse D.} and Rollison, {Dana E.} and Thomas, {John W.} and Waclawiw, {Myron A.} and Liu, {Jane Jijun} and {Al Baghdadi}, Tareq and Walter, {Matthew J.} and Rafael Bejar and Gorak, {Edward J.} and Starczynowski, {Daniel T.} and Foran, {James M} and Cerhan, {James R} and Moscinski, {Lynn C.} and Komrokji, {Rami S.} and Deeg, {H. Joachim} and Epling-Burnette, {Pearlie K.}",
year = "2019",
month = "1",
day = "1",
doi = "10.1080/10428194.2019.1616186",
language = "English (US)",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Informa Healthcare",

}

TY - JOUR

T1 - The National MDS Natural History Study

T2 - design of an integrated data and sample biorepository to promote research studies in myelodysplastic syndromes

AU - Sekeres, Mikkael A.

AU - Gore, Steven D.

AU - Stablein, Donald M.

AU - DiFronzo, Nancy

AU - Abel, Gregory A.

AU - DeZern, Amy E.

AU - Troy, Jesse D.

AU - Rollison, Dana E.

AU - Thomas, John W.

AU - Waclawiw, Myron A.

AU - Liu, Jane Jijun

AU - Al Baghdadi, Tareq

AU - Walter, Matthew J.

AU - Bejar, Rafael

AU - Gorak, Edward J.

AU - Starczynowski, Daniel T.

AU - Foran, James M

AU - Cerhan, James R

AU - Moscinski, Lynn C.

AU - Komrokji, Rami S.

AU - Deeg, H. Joachim

AU - Epling-Burnette, Pearlie K.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Myelodysplastic syndromes (MDS), a spectrum of heterogeneous hematopoietic stem cell diseases, vary in clinical severity, response to therapy, and propensity toward progression to acute myeloid leukemia. These are acquired clonal disorders resulting from somatic mutations within the hematopoietic stem or progenitor cell population. Understanding the natural history and the risk of developing leukemia and other adverse outcomes is dependent on access to well-annotated biospecimens linked to robust clinical and molecular data. To facilitate the acquisition and distribution of MDS biospecimens to the wider scientific community and support scientific discovery in this disease, the National MDS Natural History study was initiated by the National Heart, Lung, and Blood Institute (NHLBI) and is being conducted in collaboration with community hospitals and academic medical centers supported by the National Cancer Institute (NCI). The study will recruit up to 2000 MDS patients or overlapping myeloproliferative neoplasms (MDS/MPN) and up to 500 cases of idiopathic cytopenia of undetermined significance (ICUS). The National MDS Natural History Study (NCT02775383) will offer the world’s largest disease-focused tissue biobank linked to longitudinal clinical and molecular data in MDS. Here, we report on the study design features and describe the vanguard phase of 200 cases. The study assembles a comprehensive clinical database, quality of life results, laboratory data, histopathology slides and images, genetic information, hematopoietic and germline tissues representing high-quality biospecimens and data from diverse centers across the United States. These resources will be available to the scientific community for investigator-initiated research.

AB - Myelodysplastic syndromes (MDS), a spectrum of heterogeneous hematopoietic stem cell diseases, vary in clinical severity, response to therapy, and propensity toward progression to acute myeloid leukemia. These are acquired clonal disorders resulting from somatic mutations within the hematopoietic stem or progenitor cell population. Understanding the natural history and the risk of developing leukemia and other adverse outcomes is dependent on access to well-annotated biospecimens linked to robust clinical and molecular data. To facilitate the acquisition and distribution of MDS biospecimens to the wider scientific community and support scientific discovery in this disease, the National MDS Natural History study was initiated by the National Heart, Lung, and Blood Institute (NHLBI) and is being conducted in collaboration with community hospitals and academic medical centers supported by the National Cancer Institute (NCI). The study will recruit up to 2000 MDS patients or overlapping myeloproliferative neoplasms (MDS/MPN) and up to 500 cases of idiopathic cytopenia of undetermined significance (ICUS). The National MDS Natural History Study (NCT02775383) will offer the world’s largest disease-focused tissue biobank linked to longitudinal clinical and molecular data in MDS. Here, we report on the study design features and describe the vanguard phase of 200 cases. The study assembles a comprehensive clinical database, quality of life results, laboratory data, histopathology slides and images, genetic information, hematopoietic and germline tissues representing high-quality biospecimens and data from diverse centers across the United States. These resources will be available to the scientific community for investigator-initiated research.

KW - biorepository

KW - Myelodysplastic syndromes

KW - natural history

KW - quality of life

UR - http://www.scopus.com/inward/record.url?scp=85066127825&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85066127825&partnerID=8YFLogxK

U2 - 10.1080/10428194.2019.1616186

DO - 10.1080/10428194.2019.1616186

M3 - Article

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

ER -